We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Read MoreHide Full Article
Key Takeaways
XENE posted a narrower-than-expected Q2 loss and expects its cash position to support operations into 2029.
XENE remains on track to file an NDA for azetukalner in focal onset seizures in the third quarter of 2026.
Xenon continues advancing late- and early-stage studies across epilepsy, MDD, BPD and acute pain programs.
Xenon Pharmaceuticals (XENE - Free Report) reported a loss of $1.11 per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.16 per share. The company had incurred a loss of $1.07 per share in the year-ago quarter.
In the reported quarter, Xenon did not generate any revenues. Due to the lack of a marketed product, the company recognizes only periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX - Free Report) .
XENE's Q2 Results in Detail
In the second quarter, research and development (R&D) expenses increased 32.3% year over year to $99.2 million. The uptick was primarily due to increased expenses related to Xenon’s ongoing azetukalner late-stage studies in epilepsy, major depressive disorder (MDD) and bipolar depression (BPD), as well as manufacturing activities supporting the planned regulatory submission. Costs incurred in supporting the early-stage studies of XEN1701 and XEN1120, as well as increased personnel-related costs, also contributed to higher R&D expenses.
General and administrative expenses totaled $23.9 million in the reported quarter, up 24.4% year over year due to higher personnel expenses from a larger workforce and increased professional and consulting fees.
Xenon had cash, cash equivalents and marketable securities worth $1.2 billion as of June 30, 2026 compared with $1.3 billion as of March 31, 2026. Based on its current operating plans, Xenon expects its existing cash position to support operations into 2029.
Year to date, XENE shares have gained 44% compared with the industry’s 4.3% growth.
Image Source: Zacks Investment Research
XENE's Pipeline Updates
Xenon is advancing azetukalner, its lead investigational therapy, through a late-stage clinical development program for the treatment of focal onset seizures (FOS). The company's phase III epilepsy program includes two similarly designed studies, X-TOLE2 and X-TOLE3.
In March, Xenon announced positive top-line data from the phase III X-TOLE2 study, which met its primary endpoint. The company remains on track to submit a new drug application for azetukalner in FOS in the third quarter of 2026 following a successful pre-NDA meeting with the FDA. If approved, azetukalner would become the only KV7 potassium channel opener available for treating epilepsy.
The identical phase III X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions. Patient enrollment outside of Japan is expected to be completed in 2026. XENE is evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study, which is currently enrolling patients.
Two of Xenon’s three planned phase III clinical studies, X-NOVA2 and X-NOVA3, evaluating azetukalner in patients with MDD, are currently underway, with top-line data from X-NOVA2 expected in the first half of 2027.
XENE’s first of two phase III clinical studies, X-CEED, evaluating azetukalner in patients with BPD I or II, is also currently ongoing.
Xenon has initiated two separate early-stage studies evaluating XEN1120 and XEN1701 in healthy adult participants, targeting Kv7 and Nav1.7, respectively. Both studies are expected to be completed in the second half of 2026, supporting the initiation of separate phase II proof-of-concept studies in acute pain.
XENE, in collaboration with Neurocrine Biosciences, is currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, in a phase I study as a potential treatment for certain types of epilepsy. Top-line data is expected in 2027.
Xenon Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Over the past 60 days, earnings per share estimates for Harmony Biosciences have increased from $3.20 to $3.33 for 2026. Over the same period, estimates for earnings per share increased from $3.64 to $3.92 for 2027. HRMY shares have risen 3.5% year to date.
Harmony Biosciences missed on earnings in three of the trailing four quarters and beat in the remaining one, delivering an average negative surprise of 13.97%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $5.31 from $4.81. LQDA shares have gained 159.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Key Takeaways
Xenon Pharmaceuticals (XENE - Free Report) reported a loss of $1.11 per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.16 per share. The company had incurred a loss of $1.07 per share in the year-ago quarter.
In the reported quarter, Xenon did not generate any revenues. Due to the lack of a marketed product, the company recognizes only periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX - Free Report) .
XENE's Q2 Results in Detail
In the second quarter, research and development (R&D) expenses increased 32.3% year over year to $99.2 million. The uptick was primarily due to increased expenses related to Xenon’s ongoing azetukalner late-stage studies in epilepsy, major depressive disorder (MDD) and bipolar depression (BPD), as well as manufacturing activities supporting the planned regulatory submission. Costs incurred in supporting the early-stage studies of XEN1701 and XEN1120, as well as increased personnel-related costs, also contributed to higher R&D expenses.
General and administrative expenses totaled $23.9 million in the reported quarter, up 24.4% year over year due to higher personnel expenses from a larger workforce and increased professional and consulting fees.
Xenon had cash, cash equivalents and marketable securities worth $1.2 billion as of June 30, 2026 compared with $1.3 billion as of March 31, 2026. Based on its current operating plans, Xenon expects its existing cash position to support operations into 2029.
Year to date, XENE shares have gained 44% compared with the industry’s 4.3% growth.
Image Source: Zacks Investment Research
XENE's Pipeline Updates
Xenon is advancing azetukalner, its lead investigational therapy, through a late-stage clinical development program for the treatment of focal onset seizures (FOS). The company's phase III epilepsy program includes two similarly designed studies, X-TOLE2 and X-TOLE3.
In March, Xenon announced positive top-line data from the phase III X-TOLE2 study, which met its primary endpoint. The company remains on track to submit a new drug application for azetukalner in FOS in the third quarter of 2026 following a successful pre-NDA meeting with the FDA. If approved, azetukalner would become the only KV7 potassium channel opener available for treating epilepsy.
The identical phase III X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions. Patient enrollment outside of Japan is expected to be completed in 2026. XENE is evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study, which is currently enrolling patients.
Two of Xenon’s three planned phase III clinical studies, X-NOVA2 and X-NOVA3, evaluating azetukalner in patients with MDD, are currently underway, with top-line data from X-NOVA2 expected in the first half of 2027.
XENE’s first of two phase III clinical studies, X-CEED, evaluating azetukalner in patients with BPD I or II, is also currently ongoing.
Xenon has initiated two separate early-stage studies evaluating XEN1120 and XEN1701 in healthy adult participants, targeting Kv7 and Nav1.7, respectively. Both studies are expected to be completed in the second half of 2026, supporting the initiation of separate phase II proof-of-concept studies in acute pain.
XENE, in collaboration with Neurocrine Biosciences, is currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, in a phase I study as a potential treatment for certain types of epilepsy. Top-line data is expected in 2027.
Xenon Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Xenon Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Xenon Pharmaceuticals Inc. Quote
XENE's Zacks Rank & Stocks to Consider
Xenon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, earnings per share estimates for Harmony Biosciences have increased from $3.20 to $3.33 for 2026. Over the same period, estimates for earnings per share increased from $3.64 to $3.92 for 2027. HRMY shares have risen 3.5% year to date.
Harmony Biosciences missed on earnings in three of the trailing four quarters and beat in the remaining one, delivering an average negative surprise of 13.97%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $5.31 from $4.81. LQDA shares have gained 159.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.